药物聚类预测加巴喷丁类药物新安全性特征:与电压门控钙通道配体药物的比较
本研究基于VigiBase数据库,提取与加巴喷丁类药物、心血管钙通道阻滞剂(CCBs)及抗惊厥药相关的报告比值比显著失衡的不良反应(ADR),通过主成分分析预处理后行层次聚类,将16种药物和65种ADR分为3类。加巴喷丁类药物与部分二氢吡啶类CCBs及Cav阻断性抗惊厥药聚为一类,提示安全性特征重叠,可用于预测未识别ADR。
要点
- 加巴喷丁类药物与部分二氢吡啶类CCBs及抗惊厥药安全性特征重叠。
- 聚类结果在四项敏感性分析中一致,提示稳健。
- 可利用共享分子靶点和ADR特征的较老药物信息预测加巴喷丁类新ADR。
核心结论
- 加巴喷丁类药物的安全性特征与部分二氢吡啶类CCBs及Cav阻断性抗惊厥药重叠。
- 该结果可用于从共享分子靶点和ADR特征的较老药物中预测加巴喷丁类药物的未识别ADR。
研究设计与样本
- 基于VigiBase数据库提取与加巴喷丁类、CCBs或抗惊厥药相关的至少一个报告比值比显著失衡的ADR。
- 经主成分分析预处理后行层次聚类,并通过四项敏感性分析验证稳健性。
- 共纳入16种药物和65种ADR。
主要发现
- 聚类1包含加巴喷丁类药物及异radipine、nicardipine、lacidipine、lercanidipine、ethosuximide、levetiracetam、zonisamide和nimodipine共9种药物。
- 聚类2包含地尔硫䓬和维拉帕米2种药物。
- 聚类3包含氨氯地平、非洛地平、硝苯地平和尼群地平4种药物。
- 聚类结果在所有敏感性分析中一致。
临床怎么用
- 临床可参考共享分子靶点和ADR特征的较老药物信息,预判加巴喷丁类药物的潜在未识别ADR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Gabapentin and pregabalin bind to α2-δ subunit of voltage-gated calcium channels (Cav ). Other drugs targeting Cav include cardiovascular calcium channel blockers (CCBs) and anticonvulsants (levetiracetam, ethosuximide and zonisamide). In addition to pharmacodynamics, the safety profile of gabapentinoids seems to overlap with the one of cardiovascular CCBs (oedema) and Cav -blocking anticonvulsants (suicide and ataxia). The objective of this study was to cluster the safety profile of different Cav -ligand drugs by focusing on whether gabapentinoids present a distinct adverse drug reaction (ADR) signature from cardiovascular CCBs and anticonvulsants. METHODS: We extracted all ADRs with at least one significant disproportionate reporting (reporting odds ratio) related to gabapentinoids, CCBs or anticonvulsants in VigiBase. After principal component analysis preprocessing, a hierarchical ascendent classification was performed to cluster gabapentinoids and other Cav -ligand drugs that share a similar ADR signature. The robustness of the results was determined through four sensitivity analyses, varying on the dataset or the clustering method. RESULTS: A total of 16 drugs and 65 ADRs were included. Gabapentinoids were in Cluster #1, which included eight other drugs (isradipine, nicardipine, lacidipine, lercanidipine, ethosuximide, levetiracetam, zonisamide and nimodipine). Cluster #2 contained two drugs (diltiazem and verapamil) and Cluster #3 contained four drugs (amlodipine, felodipine, nifedipine and nitrendipine). The clustering results were consistent in all sensitivity analyses. CONCLUSIONS: The safety profile of gabapentinoids overlaps with those of some dihydropyridine CCBs and Cav -blocking anticonvulsants. These results could be used to anticipate some unidentified ADRs of gabapentinoids from information accumulated with older drugs and sharing a common molecular target and ADR signature.
引用
- Viguier T, Agier MS, Jonville-Béra AP, et al. Drug clustering to anticipate new aspects of drug safety profile: Application to gabapentinoids and other voltage-gated calcium channel ligand drugs. Br J Clin Pharmacol. 2023. PMID: 37872105. doi:10.1111/bcp.15931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。